Trending:
-
20 September 2018
Measles cases hit record high in Europe?
The World Health Organization (WHO) has warned that the measles epidemic sweeping Europe has reached an eight-year high, with more than 41,000 cases reported in the first six months of...
-
18 September 2018
EADV 2018: Dupixent shows strong results in phase III Trial for atopic dermatitis
Trial results for Regeneron Pharmaceutical/Sanofi’s pivotal 16 week Phase III trial testing the safety and efficacy of Dupixent (dupilumab) in adolescent patients (ages 12–17 years) with moderate-severe atopic dermatitis was...
-
18 September 2018
Strong growth expected for the orphan and rare dermatology premium products market
The current orphan and rare dermatology therapeutics market is a highly genericised therapy area, which accounts for its small premium product market size.
-
18 September 2018
AdaptVac and the emergence of virus-like particle vaccines in breast cancer
This week, AdaptVac announced the acceptance of a notice of allowance from the US Patent and Trademark Office (USPTO) for its patent application pursuing the virus-like particle (VLP) technology platform.
-
18 September 2018
Patients recruited to blood cancer trial backed by Leukemia & Lymphoma Society
Approximately 340 patients have been enrolled in the Phase I/II BEAT AML Master Trial testing seven experimental targeted therapies for newly diagnosed acute myeloid leukaemia, a cancer of the blood...
-
14 September 2018
Could Bristol-Myers Squibb change the psoriasis market?
The psoriasis drug market is a fiercely competitive one, strongly held by large pharmaceutical companies that offer biological treatments. These treatments target pro-inflammatory cytokines, such as tumour necrosis factor alpha...
-
14 September 2018
EADV 2018: New analysis shows positive results for atopic dermatitis treatment
Data shown at the 2018 European Academy of Dermatology and Venerology (EADV) Congress from the longitudinal analysis of the AD-301 and AD-302 Phase III studies on 2% crisaborole ointment being...
-
13 September 2018
EADV 2018: first real-life data from studies of atopic dermatitis patients on Dupilumab
The first data on real-life adult atopic dermatitis patients being treated with Sanofi and Regeneron’s dupilumab was revealed at the proceedings of the 2018 European Academy of Dermatology and Venereology...
-
11 September 2018
Syphilis will remain a global burden in the next decade
Syphilis continues to be a global disease burden with a high and growing number of new cases each year.
-
11 September 2018
The return of blockbusters through immuno-oncology
Rising research and development (R&D) in cancer immunotherapy has resulted in the introduction of treatment options that are more effective and efficient.
